The 3Mg Study: A randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma

The 3Mg Study aims to determine whether IV or nebulised magnesium sulphate should be standard first-line treatment for patients with acute severe asthma. The trial will test whether IV or nebulised magnesium sulphate can reduce the proportion of patients who require admission at initial presentation or during the following week, and/or improve the patient´s assessment of their breathlessness over two hours after initiation of treatment